{"id":29083,"date":"2024-12-16T16:05:59","date_gmt":"2024-12-16T15:05:59","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=29083"},"modified":"2024-12-19T15:39:26","modified_gmt":"2024-12-19T14:39:26","slug":"pharming-offentliggor-ett-rekommenderat-kontanterbjudande-till-aktieagarna-i-abliva","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/pharming-offentliggor-ett-rekommenderat-kontanterbjudande-till-aktieagarna-i-abliva\/","title":{"rendered":"Pharming offentligg\u00f6r ett rekommenderat kontanterbjudande till aktie\u00e4garna i Abliva"},"content":{"rendered":"<p class=\"preamble\">Pharming Group N.V., genom det hel\u00e4gda dotterbolaget Pharming Technologies B.V., offentligg\u00f6r ett rekommenderat kontanterbjudande till aktie\u00e4garna i Abliva AB att \u00f6verl\u00e5ta samtliga aktier i Abliva till Pharming till ett pris om 0,45 kronor kontant per aktie. Erbjudandet v\u00e4rderar samtliga utest\u00e5ende aktier i Abliva till cirka SEK 725 miljoner.<\/p>\n<p>Pharming \u00e4r ett globalt biofarmaceutiskt f\u00f6retag som kommersialiserar och utvecklar en innovativ portf\u00f6lj av proteiners\u00e4ttningsbehandlingar och precisionsmedicin, inklusive sm\u00e5 molekyler och biologiska l\u00e4kemedel. Pharming har sitt huvudkontor i Leiden, Nederl\u00e4nderna, och har anst\u00e4llda \u00f6ver hela v\u00e4rlden som hj\u00e4lper patienter p\u00e5 \u00f6ver 30 marknader i Nordamerika, Europa, Mellan\u00f6stern, Afrika och Asien-Stillahavsregionen. Pharmings aktier \u00e4r upptagna till handel p\u00e5 Euronext Amsterdam och dess American Depositary Shares (ADSs) \u00e4r upptagna till handel p\u00e5 Nasdaq Global Market.<\/p>\n<p>Abliva uppt\u00e4cker och utvecklar l\u00e4kemedel f\u00f6r behandling av mitokondriell sjukdom. Abliva \u00e4r baserat i Lund och dess aktier \u00e4r upptagna till handel p\u00e5 Nasdaq Stockholm, Small Cap.<\/p>\n<p>Pharming r\u00e5dges av Mannheimer Swartling i samband med erbjudandet.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharming Group N.V., genom det hel\u00e4gda dotterbolaget Pharming Technologies B.V., offentligg\u00f6r ett rekommenderat kontanterbjudande till aktie\u00e4garna i Abliva AB att \u00f6verl\u00e5ta samtliga aktier i Abliva\u2026<\/p>\n","protected":false},"author":18,"featured_media":29253,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-29083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":29083,"en":29085},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/29083"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=29083"}],"version-history":[{"count":1,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/29083\/revisions"}],"predecessor-version":[{"id":29084,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/29083\/revisions\/29084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/29253"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=29083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=29083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=29083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}